风湿病与肌肉骨骼试验中医生与患者对疾病活动度的总体评估:一项聚焦差异原因的元研究
该元研究从Cochrane肌肉骨骼组系统评价中抽样 randomized controlled trials(RCT),比较医生与患者对疾病活动度的总体评估。共纳入70项试验、116个随机对照比较、7种疾病,合并ROR=1.15(95%CI 1.07-1.23),医生评估更倾向于实验干预;类风湿关节炎ROR=1.33(95%CI 1.13-1.56),其余疾病ROR=1.04(95%CI 0.95-1.14)。
要点
- 医生与患者对疾病活动度的总体评估在风湿病试验中存在差异,医生更倾向实验干预。
- 合并ROR=1.15(95%CI 1.07-1.23),异质性I²=89.1%。
- 类风湿关节炎ROR=1.33(95%CI 1.13-1.56),其余疾病ROR=1.04(95%CI 0.95-1.14)。
核心结论
- 在风湿病比较有效性研究中,医生对疾病活动度的总体评估比患者更倾向于实验干预。
研究设计与样本
- 通过Cochrane系统评价数据库从Cochrane肌肉骨骼组系统评价中抽样纳入RCT,要求同时报告医生与患者总体评估的定量分析,采用混合效应元回归模型,以ROR为因变量。
主要发现
- 共纳入70项试验、116个随机对照比较、7种疾病(强直性脊柱炎、纤维肌痛、银屑病关节炎、骨关节炎、类风湿关节炎、系统性红斑狼疮和痛风)。
- 所有有效性比较的合并ROR=1.15(95%CI 1.07-1.23),医生评估显著倾向于实验干预,异质性I²=89.1%。
- 类风湿关节炎ROR=1.33(95%CI 1.13-1.56),其余疾病ROR=1.04(95%CI 0.95-1.14)。
关键数值与推荐
- ROR>1表示医生对实验干预的评估比患者更有利。
- 合并ROR=1.15(95%CI 1.07-1.23),异质性I²=89.1%。
- 类风湿关节炎ROR=1.33(95%CI 1.13-1.56);其余疾病ROR=1.04(95%CI 0.95-1.14)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 合并ROR基于比较间存在显著异质性(I²=89.1%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In most rheumatic and musculoskeletal diseases (RMDs), global assessments of disease activity by physicians and patients are 'anchor outcomes' in therapeutic trials evaluating whether a treatment is effective. OBJECTIVES: To compare physicians' vs patients' global assessments of disease activity in RMD trials and explore reasons for discrepancies between them. METHODS: Eligible trials were sampled from systematic reviews of treatments for RMDs by using the Cochrane database of systematic reviews (i.e., reviews from the Cochrane Musculoskeletal Group, [CMSG]). Randomized controlled trials (RCTs) of interventions for RMDs were eligible if they reported quantitative analyses of both physicians´ and patients´ global assessments at the same time point for the comparison of the same experimental intervention against the same comparator (i.e., placebo, no treatment, or other treatment). We accepted data from trial comparisons for each type of outcome, regardless of the type of intervention and type of RMD within the CMSG. Using mixed-effects meta-regression models, we assigned the dependent variable as the ratio of odds ratios (ROR) of global change with the experimental intervention, versus the control comparator. An ROR>1 would indicate that physicians rated the experimental intervention more favorable than their patients did. RESULTS: We were able to estimate the ROR (data from both physicians' and patients' global assessments) across 70 trials (116 randomized comparisons) in 7 diseases (ankylosing spondylitis, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, systemic lupus erythematosus, and gout). The combined ROR across all effectiveness comparisons were rated significantly in favor of the intervention by physicians: ROR=1.15 CI 95% (1.07 to 1.23). This combined ROR was based on a substantial heterogeneity across comparisons (I2=89.1%). Across all the stratified analyses, the type of the RMD was an informative reason for discrepancies, with a statistically significant ROR in rheumatoid arthritis ROR=1.33, CI 95% (1.13 to 1.56), unlike the ROR in all other conditions (ROR=1.04, CI 95% (0.95-1.14). CONCLUSION: In comparative effectiveness research on rheumatology, physicians' global assessments of disease activity, surprisingly, are more in favor of the experimental interventions than are those of the patients.
引用
- Lynæs C, Lynæs M, Simon LS, et al. Physicians' vs patients' global assessments of disease activity in rheumatology and musculoskeletal trials: A meta-research project with focus on reasons for discrepancies. Semin Arthritis Rheum. 2022. PMID: 35921746. doi:10.1016/j.semarthrit.2022.152074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。